Gabapentin Capsule
Product Images NDC 60760-741

7 FDA label images from St. Mary's Medical Park Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-741). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-04 (Image 04)

Image-04 (Image 04)
A formula to calculate creatinine clearance (CLCr), showing the relationship between age, weight, serum creatinine levels, and a factor of 0.85 for female patients. This equation is used to estimate kidney function.*
FDA Label Image

Gabapentin Structural Formula (Image 05)

Gabapentin Structural Formula (Image 05)
Chemical structure of gabapentin, showing its cyclohexane ring linked to aminomethyl and carboxymethyl groups.*
FDA Label Image

Figure 1 (Image 01)

Figure 1 (Image 01)
A line graph comparing mean pain scores over an 8-week period between two groups: placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to 8, and the y-axis represents mean pain score from 0 to 10. The graph includes labels marking a 4-week dose titration period followed by a 4-week fixed dose period, showing pain scores decreasing more in the Gabapentin group than placebo over time.*
FDA Label Image

Figure 2 (Image 02)

Figure 2 (Image 02)
Line graph showing mean pain scores over 7 weeks, comparing placebo with Gabapentin dosed at 1800 mg/day and 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score from 0 to 10. Gabapentin groups show a decrease in pain score over time compared to placebo.*
FDA Label Image

Figure 3 (Image 03)

Figure 3 (Image 03)
A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) to Gabapentin (GBP) at dosages of 1800 mg, 2400 mg, and 3600 mg across two studies. The vertical axis shows percentage responders from 0% to 100%. Study 1 shows 12% response for PBO and 29% for GBP 3600 mg. Study 2 shows 14% response for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is marked with p-values less than 0.01 and 0.001.*
FDA Label Image

Image-09 (Image 09)

Image-09 (Image 09)
A scatter plot graph depicting percentage difference on the vertical axis versus daily dose in milligrams (600, 900, 1200, 1800 mg) on the horizontal axis. The graph compares three studies labeled as Study a, Study b, and Study c, each represented by different shaded squares. Data points for each study show variations in difference percentages at various dosages.*
FDA Label Image

741-60 (Gabapentin 300mg 60ct 60760 741 60)

741-60 (Gabapentin 300mg 60ct 60760 741 60)
Gabapentin 300 mg capsules label showing dosage form and strength. The label includes storage instructions, dispensing requirements, quantity (60 capsules), and manufacturer (ScieGen Pharmaceuticals, Inc.). It is packaged by St. Mary's Medical Park Pharmacy. NDC 60760-741-60 and barcode are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.